MedTrace Logo

Dynamic Thoracic Impedance as a Marker for Heart Failure Decompensation

NCT02134379 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2016-04-14

No results posted yet for this study

Summary

This pilot study proposes to perform measurements of approved thoracic impedance technology that will help answer questions in patients with decompensated heart failure.

Conditions

  • Heart Failure; With Decompensation

Interventions

DEVICE

Medtronic ICDs, CRT-Ds, and CRT-Ps

Any Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. Device must have capacity to measure thoracic impedance as described in protocol. This includes the majority of FDA-approved Medtronic devices currently in use.

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • Charles Porter, MD

    lead OTHER

Principal Investigators

  • Charles Porter, MD, FACC, FACP · University of Kansas Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02134379 on ClinicalTrials.gov